Suritozole
From Self-sufficiency
| 200px | |
| Systematic (IUPAC) name | |
|---|---|
|
5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione | |
| Identifiers | |
| CAS Number | 110623-33-1 |
| ATC code | none |
| PubChem | CID 25431 |
| Chemical data | |
| Formula | C10H10FN3S |
| Molar mass | 223.269 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel compex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Nootropics
- Organofluorides
- Triazoles
- Nervous system drug stubs
- 2Fix
